Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK obtains US OTC marketing rights to Mevacor from Merck
Mevacor is approved in the US for the treatment of elevated cholesterol levels that lifestyle changes alone cannot control and to reduce the risk of first heart attack,
Mevacor is approved in the US for the treatment of elevated cholesterol levels that lifestyle changes alone cannot control and to reduce the risk of first heart attack,
Schering-Plough is seeking marketing approval from the FDA for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar I disorder. In accepting the new
The acquisition expands Advanced Health Media’s (AHM) product and service offerings, which optimize the interactions of pharmaceutical sales and marketing professionals with healthcare professionals, improve the co-ordination of
The enFlow device is reportedly a high-performance fluid warming system that can be used to deliver flows from KVO to 200 ml/min, using advanced dry heat technology. The
This open-label, dose escalation study is expected to enroll up to 24 patients chronically infected with hepatitis C virus (HCV) and HIV. Patient dosing is continuing in the
According to the company, Surgex constitutes a blend of extended release proteins, anti-oxidants, amino acids and whole food calories to meet the multi-nutritional needs of strength, speed, and
In tests, the treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 led to reduction of autoantibody production and amelioration of disease symptoms. A significant
The company has announced the dosing of the first patient and the study is designed to enroll at least 12 more patients. The trial will evaluate the clinical
The covered small interfering RNAs (siRNAs) are 15 to 49 nucleotide pairs in length. Alnylam said that the new Kreutzer-Limmer patent extends the worldwide scope for issued claims
CytRx said that results from this clinical trial, together with previously announced clinical data from a rising multiple-dose study reported in June 2007, support the use of arimoclomol